Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19

Spyros Chalkias, Jordan Whatley, Frank Eder, Brandon Essink, Shishir Khetan, Paul Bradley, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Xiaoping Zhao, Andrea Sutherland, Xiaoying Shen, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Stephen Walsh, David C. Montefiori, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das
doi: https://doi.org/10.1101/2022.12.11.22283166

Data Availability

As the trial is ongoing, access to patient-level data and supporting clinical documents by qualified external researchers may be available upon request and subject to review once the trial is complete.

Back to top
Posted December 13, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19
Spyros Chalkias, Jordan Whatley, Frank Eder, Brandon Essink, Shishir Khetan, Paul Bradley, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Xiaoping Zhao, Andrea Sutherland, Xiaoying Shen, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Stephen Walsh, David C. Montefiori, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das
medRxiv 2022.12.11.22283166; doi: https://doi.org/10.1101/2022.12.11.22283166
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area